DX5057
Facioscapulohumeral Muscular Dystrophy (FSHD)
PreclinicalIND-Enabling studies planned for 2025
Key Facts
Indication
Facioscapulohumeral Muscular Dystrophy (FSHD)
Phase
Preclinical
Status
IND-Enabling studies planned for 2025
Company
About Altay Therapeutics
Altay Therapeutics is a private, preclinical-stage biotech focused on unlocking transcription factors as therapeutic targets. The company's core technology is a therapeutic area-agnostic platform that identifies novel allosteric sites on transcription factors to design highly selective oral inhibitors. With its lead FSHD program expected to enter IND-enabling studies in 2025 and a STAT3 inhibitor in lead optimization, Altay is positioning itself as a leader in a challenging but high-potential drug discovery space, supported by grants and recognition from major pharmaceutical companies.
View full company profileTherapeutic Areas
Other Facioscapulohumeral Muscular Dystrophy (FSHD) Drugs
| Drug | Company | Phase |
|---|---|---|
| AOC Program | Avidity Biosciences | Clinical |
| DYNE-301 | Dyne Therapeutics | Phase 1/2 |
| Losmapimod (FHD-286) | Fulcrum Therapeutics | Phase 3 |